Clinical Trial Update: A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the long-term safety, tolerability, and effectiveness of extended-release paliperidone in people with schizophrenia has been complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone Extended Release (paliperidone extended-release)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED